Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

Ardent Health's 2025 Net Income Drops to $230.1M

Ardent Health reported full-year 2025 net income of $230.1 million, down from $299.7 million in 2024, even as revenue-related operating adjustments shifted in several directions.

Adjusted EBITDA fell to $447.3 million from $498.5 million a year earlier, a decline of $51.2 million. The drop came despite higher depreciation and amortization, which rose to $155.7 million from $146.3 million, and a larger equity-based compensation charge of $39.3 million versus $18.0 million in 2024.

Interest expense eased to $55.2 million from $65.6 million, while income tax expense declined to $56.2 million from $63.4 million. Noncontrolling interest earnings were $94.3 million, compared with $89.4 million in 2024.

Cybersecurity incident recoveries, net improved slightly to a $22.7 million benefit in 2025 from a $21.5 million benefit in 2024. Restructuring, exit and acquisition-related costs were little changed at $13.3 million, versus $12.8 million a year earlier. Epic-related implementation costs increased to $4.8 million from $3.2 million. Loss on extinguishment and modification of debt rose to $7.3 million from $3.4 million.

For the fourth quarter, net income was $74.3 million, with Adjusted EBITDAR at $175.7 million. That quarterly EBITDAR included $41.8 million of rent expense payable to REITs, made up of $38.9 million tied to Ventas leases and $2.9 million tied to the MPT lease.

For the full year, rent expense payable to REITs totaled $164.3 million, including $152.9 million related to Ventas and $11.4 million related to MPT. Today the company's shares have moved 1.39% to a price of $10.91. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS